xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

458

KUANetal.

and neck in the United States. Health Qual Life Outcomes . 2020;18(1):195. https://doi.org/10.1186/s12955-020-01424-x 2177. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetux imab for squamous-cell carcinoma of the head and neck. N Engl J Med . 2006;354(6):567-578. https://doi.org/10.1056/ NEJMoa053422 2178. Rasch CRN, Hauptmann M, Schornagel J, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer . 2010;116(9):2159-2165. https://doi.org/10.1002/cncr.24916 2179. Heukelom J, Lopez-Yurda M, Balm AJM, et al. Late follow up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer: late follow-up of the RAD PLAT trial. Head Neck . 2016;38(S1):E488-E493. https://doi. org/10.1002/hed.24023 2180. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer . 2012;12(4):252-264. https:// doi.org/10.1038/nrc3239 2181. Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2019, NCCN clin ical practice guidelines in oncology. J Natl Compr Canc Netw . 2019;17(3):255-289. https://doi.org/10.6004/jnccn.2019.0013 2182. Ferris RL, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. NEngl JMed . 2016;375(19):1856-1867. https://doi.org/10.1056/ NEJMoa1602252 2183. Seiwert TY, Burtness B, Mehra R, et al. Safety and clin ical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol . 2016;17(7):956-965. https://doi.org/10.1016/ S1470-2045(16)30066-3 2184. Cohen EEW, Bell RB, Bifulco CB, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunotherapy Cancer . 2019;7(1):184. https://doi.org/10.1186/s40425-019-0662-5 2185. Chow LQM, Haddad R, Gupta S, et al. Antitumor activ ity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell car cinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol . 2016;34(32):3838-3845. https://doi.org/10. 1200/JCO.2016.68.1478 2186. Powell SF, Gold KA, Gitau MM, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study. J Clin Oncol . 2020;38(21):2427-2437. https://doi.org/10.1200/ JCO.19.03156 2187. Mehra R, Seiwert TY, Gupta S, et al. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer . 2018;119(2):153-159. https://doi.org/10.1038/s41416-018-0131-9 2188. Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta analysis. Ther Adv Respir Dis . 2016;10(3):183-193. https://doi. org/10.1177/1753465816636557

sis: preliminary results. Laryngoscope Investig Otolaryngol . 2020;5(1):19-23. https://doi.org/10.1002/lio2.345 2164. Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. NEngl JMed . 2007;357(17):1695-1704. https://doi.org/ 10.1056/NEJMoa071028 2165. Ghi MG, Paccagnella A, Ferrari D, et al. Induction TPF followed by concomitant treatment versus concomitant treat ment alone in locally advanced head and neck cancer. A phase II–III trial. Ann Oncol . 2017;28(9):2206-2212. https://doi.org/ 10.1093/annonc/mdx299 2166. Paccagnella A, Ghi MG, Loreggian L, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradio therapy in locally advanced head and neck cancer: a phase II randomized study. AnnOncol . 2010;21(7):1515-1522. https:// doi.org/10.1093/annonc/mdp573 2167. Larive S, Bombaron P, Riou R, et al. Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial. Lung Cancer . 2002;35(1):1-7. https://doi. org/10.1016/S0169-5002(01)00288-4 2168. Frizziero M, Spada F, Lamarca A, et al. Carboplatin in combination with oral or intravenous etoposide for extra pulmonary, poorly-differentiated neuroendocrine carcino mas. Neuroendocrinology . 2019;109(2):100-112. https://doi.org/ 10.1159/000497336 2169. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEngl JMed . 2002;346(4):235 242. https://doi.org/10.1056/NEJMoa011795 2170. Furtado M, Johnson R, Kruger A, Turner D, Rule S. Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. Br J Haematol . 2015;168(1):55-62. https://doi.org/10.1111/bjh.13101 2171. Kim R, Hahn S, Shin J, et al. The effect of induction chemotherapy using docetaxel, cisplatin, and fluorouracil on survival in locally advanced head and neck squamous cell car cinoma: a meta-analysis. Cancer Res Treat . 2016;48(3):907-916. https://doi.org/10.4143/crt.2015.359 2172. Bernadach M, Lapeyre M, Dillies AF, et al. Predictive factors of toxicity of TPF induction chemotherapy for locally advanced head and neck cancers. BMCCancer . 2021;21(1):360. https:// doi.org/10.1186/s12885-021-08128-5 2173. Nishimura G, Tsukuda M, Mikami Y, et al. The efficacy and safety of concurrent chemoradiotherapy for maxillary sinus squamous cell carcinoma patients. Auris Nasus Larynx . 2009;36(5):547-554. https://doi.org/10.1016/j.anl.2008.11.002 2174. Tsan YH, Wung SH, Lin MW, Lo WL, Wang YJ. Predictors of quality of life change in head-and-neck cancer survivors dur ing concurrent chemoradiotherapy: a prospective study. Asia Pac J Oncol Nurs . 2021;8(3):237-245. https://doi.org/10.4103/ 2347-5625.311132 2175. Ye A, Hay J, Laskin J, Wu J, Ho C. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab. J Can Res Ther . 2013;9(4):607-612. https://doi.org/10.4103/0973-1482.126455 2176. Aggarwal H, Punekar RS, Li L, Carter GC, Walker MS. Quality of life analysis of patients treated with cetuximab or cisplatin for locoregionally advanced squamous cell carcinoma of head